Last updated: August 14, 2026
ZIMHI is a prescription, high-dose naloxone hydrochloride injection developed for emergency treatment of opioid overdose. Its commercial position depends on a narrow clinical differentiation: a 5 mg prefilled intramuscular syringe intended for cases in which standard-dose naloxone may be inadequate because of fentanyl or other potent synthetic opioids. ZIMHI has a stronger dose proposition than traditional 0.4 mg or 2 mg injectable naloxone, but it competes against lower-cost generics, prescription nasal sprays, and FDA-approved over-the-counter Narcan.
Public filings do not disclose standalone ZIMHI revenue, unit volume, gross margin, or profitability. Its financial trajectory is therefore best assessed through regulatory milestones, ownership changes, channel access, pricing pressure, and the expansion of naloxone distribution.
What is ZIMHI and how does it differ from competing naloxone products?
ZIMHI contains 5 mg of naloxone hydrochloride in 0.5 mL and is supplied in a prefilled syringe for intramuscular or subcutaneous administration. The product received FDA approval in October 2021 under NDA 214697.[1]
| Attribute |
ZIMHI |
Standard injectable naloxone |
Narcan nasal spray |
Kloxxado nasal spray |
| Active ingredient |
Naloxone hydrochloride |
Naloxone hydrochloride |
Naloxone hydrochloride |
Naloxone hydrochloride |
| Dose |
5 mg/0.5 mL |
Commonly 0.4 mg/mL or 2 mg/2 mL |
4 mg/0.1 mL |
8 mg/0.1 mL |
| Delivery |
Prefilled IM or subcutaneous syringe |
Vial, ampule, or syringe |
Intranasal |
Intranasal |
| Prescription status |
Prescription product |
Prescription product |
OTC and prescription channels |
Prescription product |
| Primary differentiation |
High dose and prefilled delivery |
Low cost and clinical familiarity |
Ease of administration and broad access |
High intranasal dose |
| Main limitation |
Injection training, price, needle logistics |
Lower dose and multi-step preparation for some products |
Repeat dosing may be required |
Repeat dosing and branded pricing |
ZIMHI’s clinical and commercial thesis is that a 5 mg dose can address severe opioid toxicity with fewer sequential administrations than lower-dose products. That proposition is most relevant in fentanyl-exposed populations, where responders may encounter delayed or incomplete reversal with standard doses. FDA labeling still requires emergency medical assistance and repeat dosing when necessary.[1]
When did ZIMHI receive FDA approval and lose regulatory exclusivity?
ZIMHI was approved on October 14, 2021. The product did not receive new chemical entity exclusivity because naloxone had been marketed for decades. Its regulatory protection was instead linked to the clinical data and formulation work supporting the product’s approval.
The likely three-year regulatory exclusivity period associated with the approval would have run through October 2024 if FDA granted the standard three-year period for a new dosage form or route-related clinical submission. Regulatory exclusivity does not prevent all competing naloxone products from entering the market, particularly products relying on different formulations, delivery systems, or independent FDA pathways.
| Milestone |
Date |
Commercial effect |
| FDA approval of ZIMHI NDA 214697 |
October 14, 2021 |
Established U.S. marketing authorization |
| Initial commercial availability |
2021-2022 period |
Began prescription-channel commercialization |
| FDA approval of OTC Narcan |
March 29, 2023 |
Increased consumer access and pricing pressure |
| Likely end of three-year regulatory exclusivity |
October 2024 |
Reduced regulatory barriers to certain follow-on products |
| Current commercial position |
Public-company reporting does not isolate ZIMHI |
Standalone revenue cannot be independently measured |
The FDA approved Narcan 4 mg nasal spray for nonprescription use in March 2023. That decision expanded the market but also changed the competitive structure. ZIMHI now competes against an OTC product that is easier to administer, does not require a needle, and has strong public recognition.[2]
What patents protect ZIMHI?
ZIMHI’s protection is likely more dependent on formulation, prefilled-device, and delivery-system intellectual property than on the naloxone molecule itself. Naloxone is an old active ingredient and cannot provide meaningful molecule-level exclusivity.
Potential protection categories include:
- Stable high-concentration naloxone formulations.
- Prefilled syringe configurations.
- Dose-volume and concentration combinations.
- Injection-device components.
- Manufacturing and filling processes.
- Method-of-use claims for treatment of opioid overdose.
The FDA Orange Book should be treated as the controlling source for patents listed against NDA 214697. Public commercial materials do not establish a reliable, complete patent family or a definitive patent expiration date for every ZIMHI-related claim. A patent covering a formulation or device may expire later than the product’s three-year regulatory exclusivity, but that does not guarantee a commercially meaningful barrier if competitors use alternative formulations or delivery mechanisms.
Does ZIMHI have a strong Orange Book patent estate?
ZIMHI does not have the type of patent profile associated with a novel chemical entity. Its defensibility is narrower and more vulnerable to design-around activity.
A formulation or device patent could delay an identical copy of the product. It would not necessarily prevent:
- Generic naloxone injection in a vial or ampule.
- Generic or branded naloxone nasal spray.
- Alternative high-dose intramuscular products.
- Autoinjector or other delivery technologies.
- OTC naloxone products approved through separate applications.
For commercial forecasting, the relevant question is not whether ZIMHI has any patent protection. It is whether an asserted claim covers a practical high-dose prefilled naloxone product and survives validity and infringement challenges.
How large is the market for high-dose naloxone?
The U.S. naloxone market has expanded with opioid-overdose deaths, fentanyl exposure, public-health distribution, standing pharmacy orders, and federal and state purchasing programs. The market includes prescription dispensing, emergency medical services, hospitals, correctional facilities, schools, harm-reduction organizations, first responders, and direct public-health procurement.
Market growth has not translated evenly into branded revenue. Much of the volume is purchased through:
- State opioid settlement programs.
- Medicaid and public-health contracts.
- Institutional tenders.
- Generic injectable products.
- OTC retail channels.
- Nonprofit and community distribution programs.
The Centers for Disease Control and Prevention reported more than 80,000 drug-overdose deaths involving opioids in the 12-month period ending in 2023, although the overall overdose trend began to moderate in parts of the period.[3] The epidemiology supports continued naloxone demand, but demand growth is increasingly volume-driven and price-sensitive.
What is ZIMHI’s target market?
ZIMHI is most relevant to buyers that value dose concentration, rapid deployment, and reduced preparation steps:
- Emergency medical services.
- Police and fire departments.
- Correctional institutions.
- Hospitals and emergency departments.
- High-risk opioid-treatment programs.
- Public-health programs serving fentanyl-exposed populations.
Its fit is weaker in settings that prioritize the lowest acquisition cost or broad nonprofessional distribution. Community organizations often prefer nasal products because they are easier for untrained users to administer and avoid accidental needle exposure.
How does ZIMHI compare with Narcan, Kloxxado, and generic naloxone?
ZIMHI’s principal advantage is its 5 mg injectable dose. Its principal disadvantage is the need for injection. Narcan has the strongest accessibility profile because it is OTC and nasal. Kloxxado offers an 8 mg nasal dose and competes directly for buyers seeking a high-dose rescue product without injection.
| Product |
Dose positioning |
Access advantage |
Commercial vulnerability |
| ZIMHI |
5 mg IM or subcutaneous |
High-dose prefilled injection |
Prescription-only and needle-dependent |
| Narcan |
4 mg nasal |
OTC availability and simple use |
Lower dose than ZIMHI and Kloxxado |
| Kloxxado |
8 mg nasal |
High-dose, needle-free administration |
Branded pricing and repeat-dose requirements |
| Generic injectable naloxone |
Variable |
Low acquisition cost |
Lower convenience and possible preparation burden |
| RiVive |
3 mg nasal |
OTC public-health access |
Lower dose and newer commercial footprint |
ZIMHI is therefore a specialized product rather than a broad replacement for all naloxone formats. It may retain a role in professional or institutional settings where a prefilled syringe and concentrated dose are valued.
What is the financial trajectory of ZIMHI?
Standalone financial data are not publicly reported. ZIMHI was developed by Adamis Pharmaceuticals and later commercial rights and business operations became associated with US WorldMeds and its successor commercial organization. Public filings from the relevant companies report portfolio-level results rather than ZIMHI-specific sales.
| Financial metric |
Public disclosure |
| Annual ZIMHI revenue |
Not separately disclosed |
| ZIMHI unit volume |
Not separately disclosed |
| Product gross margin |
Not separately disclosed |
| Customer concentration |
Not separately disclosed at product level |
| Development cost |
Not separately disclosed in a product-specific manner |
| Product-level operating income |
Not disclosed |
| Current market share |
Not reliably disclosed in public filings |
The financial trajectory can be divided into four phases.
Development and approval phase
Before approval, value was concentrated in regulatory de-risking and the possibility of a differentiated high-dose naloxone launch. The principal investment thesis was that fentanyl-driven overdose severity would support demand for stronger naloxone products.
Early commercialization phase
The initial launch faced a crowded market and limited prescriber pull. Naloxone procurement is often controlled by public agencies, hospitals, and institutional buyers rather than individual physicians. That makes formulary access, contract pricing, reimbursement, and distribution more important than conventional pharmaceutical promotion.
Portfolio-transfer phase
ZIMHI’s association with US WorldMeds shifted the product toward a specialty-commercial model. The company’s broader portfolio has included products distributed through focused prescriber and institutional channels. Portfolio ownership can improve commercialization if it brings established payer, specialty-pharmacy, and public-sector relationships. It also limits promotional resources compared with large opioid-response or consumer-health companies.
Post-Narcan OTC phase
The 2023 OTC approval of Narcan placed a price ceiling on the consumer-facing segment. ZIMHI’s financial opportunity became more dependent on institutional contracts and high-risk clinical settings. The product can still grow in units while producing limited revenue growth if procurement agencies demand discounts or substitute lower-cost alternatives.
What pricing and reimbursement pressures affect ZIMHI?
ZIMHI’s commercial economics are exposed to three forms of pressure:
- Generic injectable substitution.
- OTC nasal-spray price competition.
- Public-sector purchasing discounts.
Naloxone is increasingly treated as a public-health commodity. Buyers may evaluate products on acquisition cost, ease of use, storage, training burden, repeat-dose requirements, and distribution reliability. A higher list price can be justified only if ZIMHI reduces total response cost or improves treatment effectiveness in a defined setting.
Medicaid and public-health reimbursement may support utilization, but reimbursement access does not guarantee profitable sales. State and federal programs often use negotiated prices, rebates, or bulk purchasing. The highest-volume channels may therefore produce lower net prices.
Which companies challenge ZIMHI?
ZIMHI faces competition from companies across several categories rather than from one direct generic equivalent.
Branded and OTC naloxone competitors
- Emergent BioSolutions, through Narcan nasal spray.
- Hikma Pharmaceuticals and other generic injectable suppliers.
- Harm Reduction Therapeutics, through RiVive nasal spray.
- Kloxxado-related commercial suppliers.
- Additional manufacturers pursuing generic or alternative naloxone delivery systems.
Indirect competitors
- Hospital pharmacies using standard injectable naloxone.
- EMS systems using multidose vials or prefilled lower-dose syringes.
- State agencies distributing no-cost nasal naloxone.
- Nonprofit organizations purchasing generic or grant-funded products.
The most serious competitive threat is substitution, not necessarily a litigation-driven generic launch against an identical ZIMHI product.
What generic entry risks exist for ZIMHI?
The probability of direct substitution is higher than the probability of a complete market collapse. Naloxone alternatives can enter through different dosage forms and regulatory routes.
Direct product risk
A competitor could seek approval for a 5 mg prefilled naloxone syringe or a clinically similar high-dose injectable product. If a relevant Orange Book patent remains listed, the applicant could file a Paragraph IV certification and trigger patent litigation under the Hatch-Waxman framework.
Formulation and device design-around risk
Competitors can avoid a ZIMHI formulation or device patent by changing:
- Concentration.
- Syringe architecture.
- Needle configuration.
- Container-closure system.
- Filling process.
- Administration instructions.
Substitution risk
Generic injectable naloxone and OTC nasal products already create practical entry risk even without an identical copy. In institutional procurement, a buyer may substitute products based on total cost and administration requirements.
No widely reported, product-specific Paragraph IV litigation materially affecting ZIMHI was identified in the public regulatory and company disclosures available for this analysis. That absence does not establish that no challenge exists at any time; it indicates that the principal observable risk is competitive substitution rather than a documented, high-profile patent case.
What manufacturing and intellectual-property barriers protect ZIMHI?
The manufacturing barrier is moderate. Naloxone itself is widely available, and injectable naloxone manufacturing is established. The more difficult elements are:
- Maintaining stability at a high concentration.
- Producing a sterile prefilled syringe.
- Controlling extractables and leachables.
- Validating container closure and dose delivery.
- Scaling aseptic filling.
- Meeting FDA requirements for combination product components.
- Maintaining supply during public-health demand surges.
These barriers can slow entry but do not create the protection associated with complex biologics, long-acting injectables, or specialized drug-device systems. ZIMHI’s manufacturing advantage would be strongest if the company had reliable contract manufacturing capacity and dependable institutional supply contracts.
How strong is the ZIMHI patent estate and commercial position?
ZIMHI has a moderate clinical differentiation but a limited exclusivity moat.
| Factor |
Assessment |
| Active ingredient protection |
Weak; naloxone is long established |
| Regulatory differentiation |
Moderate; FDA-approved 5 mg prefilled injection |
| Formulation protection |
Potentially meaningful, subject to claim scope and validity |
| Device protection |
Potentially meaningful but design-around risk exists |
| Brand recognition |
Lower than Narcan |
| OTC access |
Disadvantage versus Narcan and RiVive |
| Institutional relevance |
Moderate to strong |
| Pricing power |
Limited |
| Generic substitution risk |
Moderate to high |
| Biosimilar risk |
None; ZIMHI is a small-molecule product |
| Long-term revenue visibility |
Low because standalone sales are not disclosed |
ZIMHI’s value is tied to niche institutional demand, not broad consumer dominance. Revenue growth would require deeper penetration of EMS, correctional, hospital, and government channels, along with sustained willingness to pay for a high-dose prefilled injection.
Key Takeaways
- ZIMHI is a 5 mg prefilled injectable naloxone product approved by FDA in October 2021.
- Its main differentiation is dose strength and prefilled intramuscular delivery.
- Its main commercial weakness is prescription status and the need for injection.
- Naloxone market demand remains structurally high because of opioid and fentanyl overdoses.
- Narcan’s 2023 OTC approval increased access but intensified price and convenience competition.
- Standalone ZIMHI revenue, market share, margin, and unit volume are not publicly disclosed.
- ZIMHI has no biosimilar risk because it is a small-molecule drug.
- The patent position is likely concentrated in formulation and device claims rather than the naloxone molecule.
- Direct Paragraph IV litigation has not emerged as the principal publicly visible risk.
- Generic injectable products, OTC nasal sprays, public-health procurement, and institutional substitution create substantial market pressure.
- The product’s strongest opportunity is in professional and institutional settings that value concentrated dosing and prefilled delivery.
FAQs About ZIMHI
Is ZIMHI available over the counter?
No. ZIMHI is an FDA-approved prescription naloxone injection. Narcan and certain other naloxone nasal sprays are available through OTC channels.
Is ZIMHI more effective than Narcan?
The products use different delivery systems and doses. ZIMHI provides 5 mg by injection, while Narcan provides 4 mg intranasally. FDA labeling requires repeat dosing and emergency medical care when clinically necessary for either product.[1,2]
Does ZIMHI have biosimilar competition?
No. Biosimilars apply to biological products. ZIMHI contains the small-molecule drug naloxone hydrochloride.
Can a generic company launch a 5 mg naloxone syringe?
A company could pursue FDA approval for a comparable product, subject to applicable patents, exclusivity, product requirements, and regulatory pathway. A different naloxone dosage form could compete without copying the complete ZIMHI product.
Who owns or commercializes ZIMHI?
ZIMHI was developed by Adamis Pharmaceuticals and later commercialized through the US WorldMeds-related commercial organization. Public filings should be consulted for the current legal entity, distribution rights, and product-level commercial arrangements because ownership and portfolio structures can change.
References
-
U.S. Food and Drug Administration. (2021). ZIMHI (naloxone hydrochloride injection) prescribing information and approval materials. FDA.
-
U.S. Food and Drug Administration. (2023). FDA approves first over-the-counter naloxone nasal spray. FDA.
-
Centers for Disease Control and Prevention. (2024). Understanding the opioid overdose epidemic. U.S. Department of Health and Human Services.
-
Adamis Pharmaceuticals Corporation. (2021). Press release announcing FDA approval of ZIMHI. Adamis Pharmaceuticals.
-
Supernus Pharmaceuticals, Inc. (2023-2024). Annual reports and Securities and Exchange Commission filings. Supernus Pharmaceuticals.
